23 September 2010
European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy
- European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
Citation style for this article: Eurosurveillance editorial team. European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy. Euro Surveill. 2010;15(38):pii=19670. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19670
Date of submission:
23 September 2010
The European Medicines Agency’s Committee for Medicinal Products for Human Use today 23 September 2010 announced that it has reviewed all available data on the suspected link between narcolepsy and Pandemrix and concludes that the available evidence is insufficient to determine whether there is any link between the illness and the vaccine.
The Committee agrees that further studies are necessary to understand the issue fully and that while the review is still ongoing there is no need for Europe-wide restrictions on the use of Pandemrix. The ongoing review will take some three to six months to conclude and will require new epidemiological research to establish conclusions on the possibility of a link between Pandemrix and narcolepsy.
Until mid-September there were 81 reports from healthcare professionals which suggested narcolepsy. Of these the majority came from Sweden (34) and Finland (30), 10 from France, six from Norway and one from Portugal.
To read more about the issue, please visit the website of the European Medicines Agency: www.ema.europa.eu
The opinions expressed by authors contributing to Eurosurveillance
do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance
site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence
. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Eurosurveillance [ISSN] - ©2007-2016. All rights reserved